SCHEMBL10075686

SCHEMBL10075686

COC(=O)c1ccc(O)c2nc3c(CNC(C)=O)c(O)c(-c4c(O)c(CNC(C)=O)c5nc6c(O)ccc(C(=O)OC)c6nc5c4O)c(O)c3nc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.36
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA7 P43166 2/20 0.34
CA9 Q16790 2/20 0.34
CA14 Q9ULX7 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
PDK2 Q15119 1/20 0.34
PDK4 Q16654 1/20 0.34
EGFR P00533 3/20 0.34
MAPT P10636 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
NOX4 Q9NPH5 1/20 0.34
CYP1A2 P05177 1/20 0.33
TSHR P16473 2/20 0.33
LMNA P02545 2/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10074409 0.88 KDM4E (0.40) KDM4ESMN1; SMN2CA12CA1CA2
SCHEMBL10074599 0.86 KMT2A (0.45) KDM4ESMN1; SMN2EGFRMAPTMEN1
SCHEMBL10075151 0.85 KDM4E (0.42) KDM4ESMN1; SMN2CA12CA1CA2
SCHEMBL10075152 0.85 KDM4E (0.38) KDM4ECA12CA1CA2CA7
SCHEMBL10075134 0.84 KDM4E (0.41) KDM4ESMN1; SMN2CA12CA1CA2
SCHEMBL10074598 0.83 HIF1A (0.44) KDM4ECA1CA2EGFRMAPT
SCHEMBL10075153 0.82 KDM4E (0.40) KDM4ECA12CA1CA2CA7
SCHEMBL10075558 0.82 MEN1 (0.39) KDM4ESMN1; SMN2CA1CA2EGFR
SCHEMBL10075149 0.82 PTGER4 (0.38) KDM4ECA12CA1CA2CA7
SCHEMBL10074893 0.79 KDM4E (0.46) KDM4ESMN1; SMN2NPSR1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US claimed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US claimed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
WO-2012088438-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES MCL1, BCL3, BCL9 KDM4E 1427/4885SMN1; SMN2 1971/4885CA12 2742/4885
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES MCL1, BCL3, BCL2L1 KDM4E 709/4885SMN1; SMN2 1917/4885CA12 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.